Qualidade de vida de pacientes com doença inflamatória intestinal em uso de terapia imunobiológica

Abstract

Objectives: To assess the quality of life of patients diagnosed with inflammatory bowel disease (IBD) using immunobiological therapy and to relate the general and by domains Inflammatory Bowel Disease Questionnaire (IBDQ)' scores to the immunobiological in use and the clinical and sociodemographic variables. Methods: Descriptive observational cross-sectional study, performed in the period from June to September 2018, in a tertiary hospital in Sergipe, which included 47 patients with a diagnosis of Crohn's Disease. The IBDQ questionnaire was applied, associated with a sociodemographic questionnaire and the clinical data and the history of the disease were analyzed. Results: Female, brown, married patients from the interior of Sergipe who never underwent any intestinal surgery represented the majority of the study participants. 24 patients were on Infliximab and 23 were on Adalimumab. Variables such as gender, type of immunobiological and duration of its use and association of therapy with other medications have been shown to influence the quality of life reported, with statistical significance (p-value <0.05). Conclusion: Further studies with larger samples are necessary to allow a more accurate delimitation of the impact of clinical and sociodemographic variables on the quality of life of patients with IBD.